TAKING STOCK
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.rBTG, the old British Technology Group, gained 15p to a 703p peak as, in the heady drug fever, the market continued to speculate about its riches, largely represented by an array of patents, licences and new products. The shares were floated at 225p in the summer.
Among the stories circulating is that BTG has clinched a licensing deal with Zeneca. It is said that the drugs giant, which yesterday launched its Diprivan intravenous anaesthetic in Japan, is taking on the marketing for a BTG cancer drug that is due to be put on sale next month.
rWensum Co, a maker of men's clothing, jumped 19p to 143p on takeover gossip. The shares have climbed 37p this week, from a year's low of 97p. Interim figures are due soon.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments